In hepatocytes, however, it stabilizes CD36 by inhibiting ubiquitination, increasing its plasma membrane localization, and accelerating up the intake of fatty acids and lipid accumulation, thereby driving MASLD progression [14]. The gene discussed is CD36; the disease is metabolic dysfunction-associated steatotic liver disease.